US BANCORP \DE\ - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$287,908
-24.5%
6,343
-6.7%
0.00%
-100.0%
Q2 2023$381,471
+11.7%
6,795
-10.0%
0.00%0.0%
Q1 2023$341,487
+21.9%
7,550
+9.6%
0.00%
Q4 2022$280,118
-67.8%
6,891
-48.3%
0.00%
-100.0%
Q3 2022$870,000
+63.2%
13,316
+51.9%
0.00%
+100.0%
Q2 2022$533,000
-10.9%
8,767
-8.0%
0.00%0.0%
Q1 2022$598,000
-9.0%
9,526
+10.0%
0.00%0.0%
Q4 2021$657,000
-18.4%
8,660
+20.3%
0.00%
-50.0%
Q3 2021$805,000
-14.7%
7,196
+23.5%
0.00%0.0%
Q2 2021$944,000
+48.0%
5,829
+11.5%
0.00%
+100.0%
Q1 2021$638,000
+230.6%
5,230
+316.1%
0.00%
Q4 2020$193,000
+93.0%
1,257
+5.2%
0.00%
Q3 2020$100,000
-40.8%
1,195
-47.9%
0.00%
Q2 2020$169,000
+74.2%
2,2950.0%0.00%
Q1 2020$97,000
-26.5%
2,295
+5.8%
0.00%
Q4 2019$132,000
+1785.7%
2,170
+1176.5%
0.00%
Q3 2019$7,000
-75.9%
170
-72.6%
0.00%
Q2 2019$29,000
+866.7%
621
+553.7%
0.00%
Q1 2019$3,0000.0%950.0%0.00%
Q4 2018$3,000
-25.0%
950.0%0.00%
Q3 2018$4,000
+300.0%
95
+143.6%
0.00%
Q1 2017$1,000390.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2023
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders